Transcenta's anti-Claudin18.2 mAb Granted Orphan Status in US
August 03, 2021 at 06:36 AM EDT
Suzhou 's Transcenta Holding was granted Orphan Drug Designation in the US for its anti-Claudin18.2 mAb in patients with or gastric or gastroesophageal junction cancers (GC/GEJ). TST001, the company's lead drug, is currently in a US Phase I trial. In preclinical studies, TST001 showed potent anti-tumor activities in tumor models of gastric cancer or gastric cancers expressing Claudin18.2. Although gastric cancer is a rare disease in the US , its incidence in China is much higher. More details....
